StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) company profile

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)

Close on Nov 17, 2026Market cap $109.97MP/E –Yield –

About LENZ Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

LENZ Therapeutics is a commercial pharmaceutical company that develops and commercializes innovative therapies to improve vision. The company’s primary product is VIZZ (aceclidine ophthalmic solution 1.44%), a once-daily, pupil-selective prescription eye drop formulated to restore near vision for up to ten hours in adults experiencing presbyopia. Operating primarily in the self-pay pharmaceutical market, the company provides treatments for adult patients dealing with age-related near-vision loss. Its products reach consumers through retail pharmacies, e-pharmacy partners, and partnerships with eye care professionals including optometrists and ophthalmologists.

The company focuses its direct commercial operations within the United States, supported by a specialized sales force of over 100 individuals targeting approximately 15,000 eye care professionals. Internationally, the company establishes licensing and distribution partnerships across multiple territories, including Greater China, Canada, South Korea, Southeast Asia, and a nine-country region in the Middle East. The provided text does not state the location of the company's headquarters.

Summary of the business section of LENZ Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
LENZ Therapeutics, Inc.
Headquarters
Solana Beach, CA
Address
201 Lomas Santa Fe Drive, Suite 300 92075
Phone
(858) 925-7000
Employees
152, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
LENZ
Former tickers
GRPH until Mar 22, 2024
Exchange
Nasdaq
IPO date
Jun 28, 2021
Shares outstanding
31M, Aug 5, 2026
Public float
$690.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-29 reverse, May 8, 2024; 1-for-7 reverse, Mar 22, 2024
SEC CIK
1815776
CUSIP
52635N103
ISIN
US52635N1037
FIGI
BBG00XDH4NZ2
Share class FIGI
BBG00XDH4P05
EIN
84-4867570

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Evert B. SchimmelpenninkPresident, CEO and Secretary, Director77,289
Daniel R. ChevallardChief Financial Officer12,886
Marc OdrichChief Medical Officer99,599
Shawn OlssonChief Commercial Officer4,733
Shelley B. ThunenDirector–
Kimberlee C. DrapkinDirector–
James W. McCollumDirector631,099
Zachary ScheinerDirector–
RA Capital Nexus Fund II, L.P.Director164,729
Frederic GuerardDirector–
Jeffrey P. GeorgeDirector5,592

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Evert Schimmelpennink
President and Chief Executive Officer
$690.00K$5.79M$538.20K$14.00K$7.04M+1%
Marc Odrich
Chief Medical Officer
$500.00K$1.66M$260.00K$14.00K$2.44M+20%
Shawn Olsson
Chief Commercial Officer
$467.50K$1.66M$243.10K$14.00K$2.39M+22%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 28, 2021
Offer price
$17.00
Securities offered
14,000,000
Gross proceeds
$238.00M
Exchange
Nasdaq
First trading day
Jun 25, 2021
First-day close
$18.50+8.8%
Lock-up ends (est.)
Dec 22, 2021

“The initial public offering price per share is $17.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 152 employees, none of whom were engaged in research and development activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 22, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 22, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 19, 2024Name changeName changed from Graphite Bio, Inc. to LENZ Therapeutics, Inc.
Dec 6, 2023MergerRegistration of securities for a merger or exchange offer (S-4)
Jun 28, 2021IPOInitial public offering priced (424B4 prospectus)
Jun 22, 2021ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?